Waters Corporation appoints Heather Knight to Board of Directors

WATERS CORP /DE/

Appointed Heather Knight effective Aug 14, 2024; Board size increased from 9 to 10.
Knight is EVP and Group President, Medical Products and Therapies at Baxter International.
Initial equity grant valued at $91,666 (50% RSU, 50% option), vesting on first anniversary.
Prorated cash retainer of $54,130 until 2025 AGM; standard non-employee director compensation.
Knight brings nearly three decades of global pharma and med device leadership experience.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Heather Knight

director

WAT · WATERS CORP /DE/

Effective: 2024-08-14
Filed: August 14, 2024, 7:59 PM ET

On August 13, 2024, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Heather Knight to the Board, effective August 14, 2024, to fill the vacancy so created.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Heather Knight was appointed as director at WATERS CORP /DE/.

Action: appointed
Role: director

Exact text from the filing

On August 13, 2024, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Heather Knight to the Board, effective August 14, 2024, to fill the vacancy so created.

View on SEC.gov

WATERS CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-24-200650

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.